Roswell Park moves forward with expanded study of CIMAvax

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Final results from the first U.S. clinical study of a Cuban immunotherapy show that CIMAvax-EGF, a treatment targeting a particular cancer survival protein, epidermal growth factor, is safe and showed promising efficacy as part of a treatment combination with nivolumab (Opdivo) in patients with advanced non-small cell lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

After reading “Breast Cancer Mortality Continues Three-Decade Decline, but Steeper Increases for Women Under 50 & AAPI Women of All Ages,” it is evident that while overall progress is being made in the fight against cancer, concerning disparities remain—particularly within the Native Hawaiian and Pacific Islander (NHPI) communities. 

Login